Cabaletta Bio
Clinical trials sponsored by Cabaletta Bio, explained in plain language.
-
Immune cell therapy takes on rare blistering skin disease
Disease control Recruiting nowThis study tests two types of engineered immune cells (CAR T cells) in 40 adults with active pemphigus vulgaris, a painful blistering skin condition. The cells are designed to target and reduce the faulty immune cells that attack the skin. The main goal is to check safety and fin…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 16, 2026 22:34 UTC
-
Engineered immune cells take aim at lupus in early trial
Disease control Recruiting nowThis study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with lupus-related kidney disease. The therapy uses a patient's own immune cells that are modified in a lab to find and destroy faulty B cells, which drive …
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 16, 2026 22:34 UTC
-
Could CAR t cells tame scleroderma? new trial launches
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
CAR t cells take on muscle disease: could this be a game changer?
Disease control Recruiting nowThis study tests a new treatment called CABA-201 for people with active inflammatory muscle diseases (myositis). It uses a patient's own immune cells, modified to target and destroy faulty immune cells. The goal is to reduce muscle inflammation and allow patients to stop or lower…
Phase: PHASE2, PHASE3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Jun 12, 2026 12:02 UTC